VEGFA-NRD1 Fusion FISH Probe
The VEGFA-NRD1 Fusion FISH Probe is used to confirm a fusion of the VEGFA and NRD1 genes. The fusion of the VEGFA and NRD1 genes has been associated with Sarcoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| VEGFA-NRD1-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-RERE | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-REOR | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-REGO | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-REGR | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-OROR | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-GORE | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-GROR | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| VEGFA-NRD1-20-AQAQ | 20 (40 μL) | 200 μL |
|
VEGFA Gene Summary
This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. [provided by RefSeq, Nov 2015]
Gene Name: Vascular Endothelial Growth Factor A
Chromosome: CHR6: 43737945 -43754223
Locus: 6p21.1
Gene Diseases
The VEGFA NRD1 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Sarcoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|